GPCR Therapeutics
PrivateLast Round
Private Equity
Jul 2, 2026
Est. Valuation
$53.56M
Total Funding Raised
$108.83M
Company Overview
GPCR Therapeutics operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series C Extension round in November 2023.
GPCR Therapeutics is a biopharmaceutical company that develops innovative cancer therapeutics by targeting G protein-coupled receptor (GPCR) heteromers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GPCR Therapeutics Comparables
Compare GPCR Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InterAx Biotech | 83% | |
| Gmax Biopharm | 83% | |
| KymaThera | 82% |
For institutional investors. Book with your work email.
GPCR Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Jul 2, 2026 | ||||
| Series C Extension | Nov 1, 2023 | ||||
| Series C | Jun 30, 2021 | ||||
| Series C | Apr 30, 2021 | ||||
| Series B | Jul 31, 2019 | ||||
Series A | Sep 30, 2016 |
For institutional investors. Book with your work email.
GPCR Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterVest | Series B, Series C, Series A |
| Kinggo Investment Partners | Series C Extension |
| Smilegate Investment | Series B, Series C |
| Kingo Investment Partners | Series C Extension |
| SUNP Corporation | Series C |
| Company K Partners | Series C, Series A |
| Medytox Venture Investment | Series B, Series C Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 76% MoM.
- Nov 23, 2023
$3.15M round led by Medytox Venture Investment
For institutional investors. Book with your work email.
GPCR Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GPCR Therapeutics's valuation, stock price, and market status.
Is GPCR Therapeutics a public or private company?
GPCR Therapeutics is a private company.
What is the current stock price of GPCR Therapeutics?
GPCR Therapeutics is a private company, so its shares have no public market price. Caplight tracks GPCR Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GPCR Therapeutics worth (valuation)?
GPCR Therapeutics's valuation is estimated at $53.6M based on funding round data.
Can I buy GPCR Therapeutics stock?
GPCR Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GPCR Therapeutics's last funding round?
GPCR Therapeutics's most recent funding round was Private Equity on July 2, 2026.
Who are the main investors in GPCR Therapeutics?
Key investors in GPCR Therapeutics include InterVest, Kinggo Investment Partners, Smilegate Investment, Kingo Investment Partners, SUNP Corporation.
Will GPCR Therapeutics IPO soon?
No public IPO plans have been announced for GPCR Therapeutics.
How can I track GPCR Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in GPCR Therapeutics's shares on secondary markets.